

20 February 2024

Scancell Holdings plc
("Scancell" or the "Company")

Change of Auditor

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces the appointment of RSM UK Audit LLP as its auditor with immediate effect, following an audit tender process.

RSM UK Audit LLP succeeds BDO LLP, who have resigned as the Company's auditors and confirmed that there are no matters relating to their resignation which should be brought to the attention of shareholders or creditors. The Board wish to thank BDO LLP for its services and support.

-ENDS-

For further information, please contact:

Scancell Holdings plc +44 (0) 20 3709 5700

Professor Lindy Durrant, CEO
Dr Jean-Michel Cosséry, Non-Executive Chairman

Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) +44 (0) 20 7710 7600

Nicholas Moore/Samira Essebiyea (Healthcare Investment Banking)

Nick Adams/Nick Harland (Corporate Broking)

WG Partners LLP (Joint Broker) +44 (0) 20 3705 9330

David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby

Panmure Gordon (UK) Limited (Joint Broker) +44 (0) 20 7886 2500

Freddy Crossley/Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

ICR Consilium +44 (0) 20 3709 5700

Mary-Jane Elliott/Matthew Neal/Chris Welsh

scancell@consilium-comms.com

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope[®] and ImmunoBody[®] for vaccines and GlyMab[®] and AvidiMab[®] for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines

to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope[®] and ImmunoBody[®]) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab[®]) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab[®]).

For further information about Scancell, please visit: <https://www.scancell.co.uk/>